Infectious Disease Surveillance, Bioterrorism, and Global Security
Cubberly Auditorium, School of Education, Stanford University
Cubberly Auditorium, School of Education, Stanford University
Professor Joshua Lederberg, a research geneticist, is Sackler Foundation Scholar, President-emeritus at The Rockefeller University in New York, and a consulting professor of the Institute for International Studies at Stanford University. Dr. Lederberg was educated at Columbia and Yale University, where he pioneered in the field of bacterial genetics with the discovery of genetic recombination in bacteria. In 1958, at the age of 33, Dr. Lederberg received the Nobel Prize in Physiology of Medicine for this work. Dr. Lederberg has been a professor of genetics at the University of Wisconsin and then at Stanford University School of Medicine, until he came to The Rockefeller University in 1978. A member of the National Academy of Sciences since 1957, and a charter member of its Institute of Medicine, Dr. Lederberg has been active in many government advisory roles, including the Defense Science Board and the Chair of the President's Cancer Panel. He has long had a keen interest in international health, and has served two terms on WHO's Advisory Health Research Council and on the boards of the Center for Strategic and International Studies (Washington) and the Council on Foreign Relations (New York). He co-chaired the IOM's study on Emerging Infections, and recently edited "Biological Weapons: Containing the Threat", published by the MIT Press.
Bechtel Center, Encina Hall
Approximately 13 speakers will be presenting throughout the day. For a detailed schedule please contact Robin Holbrook, 650-723-6270
Fairchild Auditorium
The TECH project is an international collaboration aimed at understanding patterns of technology adoption and diffusion of medical care and the effects of these patterns on patient outcomes. The team, organized from 17 developed countries, is exploring whether individuals living in countries that rapidly adopted new revascularization technologies and clot-dissolving drugs are more likely to survive heart attacks than individuals living in countries that have adopted such interventions more slowly.
The TECH project has three specific goals:
The Comparative Health Care Policy Research Project was initiated by APARC in 1990 to examine issues related to the structure and delivery of health care in Japan by utilizing contemporary social science. Further, the project was designed to make the study of Japan an integral part of international comparative health policy research. Yumiko Nishimura, the associate director, under the supervision of Daniel I. Okimoto, the principal investigator, leads the project.
Grant Building, Room S156
Stanford, California 94305-5107
Encina Commons,
615 Crothers Way, Room 200,
Stanford, CA 94305-6006
Mark Hlatky is a Professor of Health Policy (active emeritus) and a Professor of Medicine (Cardiovasular Medicine) at the Stanford University School of Medicine. His major interests are in outcomes research, evidence-based medicine, and cost-effectiveness analysis. He introduced data collection about economic and quality of life endpoints in several randomized trials, principally trials of therapies for cardiovascular disease.
Hlatky received his MD from the University of Pennsylvania, and, after residency at the University of Arizona, studied as a Robert Wood Johnson Clinical Scholar at the University of California, San Francisco. He trained in cardiology at Duke University Medical Center, and then joined the Duke faculty. He has been at the Stanford University School of Medicine since 1989.